Editas Medicine, Inc.
EDITHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. With a market capitalization of $368.6M, it sits in small-cap territory. The company develops a proprietary gene editing platform based on CRISPR technology.
Market Cap
$368.6M
Beta
2.00
P/E (TTM)
—
P/E (Fwd)
-3.19
EPS (TTM)
$-0.68
EPS (Fwd)
$-0.75
ROE
-118.8%
ROA
-23.3%
Cash
$211.6M
Total Debt
$15.5M
Free CF
-$44.3M
52W Change
-35.5%
Annual Financials
Cash vs Debt
Where EDIT stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, EDIT finished 17.83% below its 150-day moving average ($2.86) and 11.65% below its 200-day moving average ($2.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EDIT overbought or oversold?
At the October 19, 2026 close, EDIT's RSI(14) was 44.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Editas Medicine, Inc. holds $211.6M in cash against $15.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$44.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -118.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $19.7M (2022) to $40.5M (2025), reflecting a 106% increase over the period.
A beta of 2.00 means EDIT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, EDIT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Editas Medicine, Inc.'s trajectory.